Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Learn more about:
Related Clinical Trial
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Icotinib for Completed Resected IB NSCLC With EGFR Mutation Circulating Tumor DNA in Patients at High Risk for Lung Cancer Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery QUILT-3.017: Study of NEO-201 in Solid Tumors Photodynamic Therapy in Treating Patients With Lung Cancer Vaccine Treatment for Advanced Non-Small Cell Lung Cancer S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC The Tracking Molecular Evolution for NSCLC (T-MENC) Study Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung Lung Cancer Mutation Consortium Protocol The Detection of EGFR Mutations in Liquid Based Cytology Samples NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Telomere Biology in Early Adenocarcinoma of the Lung

Brief Title

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Official Title

A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Brief Summary

      The purpose of this study is to find out what effects (good and bad) a tumor vaccine
      (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer.
      Another purpose of the study is to find out the maximum tolerated dose of nivolumab in
      combination with GM.CD40L vaccine. Investigators also want to find out if the combination of
      GM.CD40L and nivolumab can boost the immune system of participants like you, and how their
      immune system reacts, both before and after the treatment.
    

Detailed Description

      This study has two parts and participants may be involved in either Phase I part or Phase II.

      Phase I: Investigators plan to enroll participants in cohorts of 6 and monitor side effects
      over a 21 day period to determine the maximum tolerated dose (MTD) of nivolumab, which will
      be given in combination with GM.CD40L. This is being done since this study involves a
      combination of treatments that have not been studied in humans before and to find the best
      dose for the Phase II part of the study.

      Phase II: Investigators plan to compare any clinical benefit in the participants who receive
      the combination of GM.CD40L vaccine with nivolumab, to participants that receive only
      nivolumab.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Phase I: Recommended Phase II Dose

Secondary Outcome

 Phase II: Overall Survival (OS)

Condition

Lung Cancer

Intervention

Nivolumab

Study Arms / Comparison Groups

 Phase I and Phase II Treatment Arm
Description:  Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

July 2018

Completion Date

July 2020

Primary Completion Date

July 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of advanced/metastatic adenocarcinoma of the lung

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0/1

          -  Chemotherapy naïve or have completed adjuvant chemotherapy for non-small cell lung
             cancer (NSCLC) >6 months prior

          -  Adequate bone marrow, renal and hepatic function

          -  Must have measurable metastatic disease according to Response Evaluation Criteria in
             Solid Tumors (RECIST) v1.1 criteria

          -  Mandatory archival tissue or willingness to undergo a fresh biopsy

          -  Life expectancy of greater than 6 months

        Exclusion Criteria:

          -  Symptomatic brain metastasis or uncontrolled central nervous system (CNS) metastasis

          -  Pregnancy or breast feeding

          -  Serious uncontrolled medical disorder or active infection that would impair the
             participant's ability to receive study treatment

          -  Prior use of a PD1 or PDL1 inhibitor

          -  Concurrent use of other anticancer approved or investigational agents is not allowed

          -  Autoimmune disorders

          -  Prior malignancy in past 2 years

          -  Systemic steroids at doses greater than 10 mg/day of prednisone or the equivalent

          -  Any other pre-existing immunodeficiency condition (including known HIV infection)
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jhanelle Gray, M.D., , 



Administrative Informations


NCT ID

NCT02466568

Organization ID

MCC-18147

Secondary IDs

1504-1392

Responsible Party

Sponsor

Study Sponsor

H. Lee Moffitt Cancer Center and Research Institute


Study Sponsor

Jhanelle Gray, M.D., Principal Investigator, H. Lee Moffitt Cancer Center and Research Institute


Verification Date

September 2019